Novo Plunges as Investors Seek More Robust Sales Targets

Novo Nordisk shares fell in early trading after the company announced plans to launch more than five blockbuster drugs and deliver more than $23 billion in new sales in coming years. Chief Executive Officer Mike Doustdar presented the targets as the Danish drugmaker has lost market share in the obesity drug sector to competitor Eli Lilly. Bloomberg reported the announcement.

Next story